Back to results
US 2013/0295097 A1Published application
Human Antibodies to Fel d1 and Methods of Use Thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJamie Orengo, Andrew J. Murphy
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJamie Orengo, Andrew J. Murphy
Estimating the term…
The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen.
An isolated human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, wherein the antibody or antigen binding fragment thereof is an isotype other than an IgA isotype.
An isolated antibody or antigen-binding fragment thereof that competes for specific binding to Fel d1 with an antibody or antigen-binding fragment comprising the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR), wherein the HCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs:
An isolated antibody or antigen-binding fragment thereof that binds the same epitope on Fel d1 as an antibody or antigen-binding fragment comprising the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR), wherein the HCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs:
A bi-specific antigen-binding molecule that specifically binds Fel d1, comprising a first antigen-binding domain that comprises a HCVR amino acid sequence as set forth in SEQ ID NO:
A bi-specific antigen-binding molecule that specifically binds Fel d1, comprising a first antigen-binding domain that comprises a HCVR amino acid sequence as set forth in SEQ ID NO:
Dependencies are inferred from the claim text.